Research programme: Clostridium difficile monoclonal antibodies - XBiotech
Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator XBiotech
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Clostridium difficile infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in USA (PO)
- 28 Apr 2021 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in USA (PO)
- 16 Mar 2017 Preclinical trials in Clostridium difficile infections in USA (PO), before March 2017